Suven Life Sciences has hit a 76% enrollment milestone in its global Phase 3 study for Masupirdine, a novel candidate targeting agitation in Alzheimer's patients. The 375-patient, double-blind study spans North America and Europe, marking significant progress for the CNS-focused biopharmaceutical company.

"This milestone reflects continued momentum in the program, completion of patient enrolment by End of calendar 2026 is certain if not earlier and last patient last visit will be in qtr. 1, 2027 enabling progression towards database lock and reporting of results potentially in Q2/ Q3-2027 calendar year. Patient enrolment activity has been accelerated through multiple additional resources, experienced investigators, medical experts, AI enabled patient identification and referral to the sites. Our goal is to advance the study towards completion with definitive timelines" said Mr. Venkat Jasti, Chairman and Managing Director of the company.

“Agitation is a common neuropsychiatric symptom of dementia due to Alzheimer’s disease, and it is associated with increased caregiver burden and need for rapid institutionalization. Current treatment options are constrained by limited efficacy and concerns about tolerability and safety. Masupirdine a pure, potent, and selective 5‑HT6 receptor antagonist with all the potential to offer a differentiated, non-dopaminergic, non-sedative approach transforming Alzheimer’s agitation (AAD) management, delivering dual impact on behavioral stabilization and cognition” said Dr. Ramakrishna Nirogi, President and CSO of Suven Life Sciences.

The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies and are representative of an Alzheimer's disease population with agitation. Suven and the CRO teams working towards the enrollment of Last Patient In (LPI) by September 2026 and Last Patient Last Visit (LPLV) by January 2027. Data readout is expected by April 2027.